Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 54

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 54
---
 of grant, with one-third of the PSUs eligible to vest based on achievement of each of the three milestones. For such PSUs, the applicable share price appreciation milestones will be reduced by the dollar value of any cash dividends paid on one of our ordinary shares during the performance period. In addition, in the event of a share split or other event described in Section 11.1 of our 2013 Equity Incentive Plan (other than a cash dividend), a corresponding adjustment will be made in the share price appreciation milestones. See “Change in Control Severance Benefits” below for more information regarding treatment of the PSUs in the event of a change in control. Following achievement of the applicable share price appreciation target, a four-year service — based vesting period will apply retroactively, commencing from the grant date (25% on February 20, 2025 and 6.25% of the PSUs on each quarterly Company vesting date thereafter).

| Share Price Appreciation Milestone                                     | ​ | ​ | Percentage ofPSUs Eligible to Vest |   |       |   | ​ |
| Achieve 20 trading day average closing share price of $12.42 or higher | ​ | ​ | ​                                  | ​ | 33.3% | ​ | ​ |
| Achieve 20 trading day average closing share price of $14.49 or higher | ​ | ​ | ​                                  | ​ | 33.3% | ​ | ​ |
| Achieve 20 trading day average closing share price of $16.56 or higher | ​ | ​ | ​                                  | ​ | 33.3% | ​ | ​ |

Employee Benefits and Perquisites We generally do not provide perquisites or other personal benefits to named executive officers that we do not provide to all of our employees. Retirement Benefits We maintain a 401(k) retirement savings plan for eligible employees, including our named executive officers. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees, including a 50% company matching contribution of up to $5,000. We do not provide a non-qualified deferred compensation program or a supplemental executive retirement plan to our named executive officers. Outstanding Equity Awards at 2024 Year-End The following table sets forth information regarding each unexercised option to purchase our ordinary shares and each restricted share unit held by each of our named executive officers as of December 31, 2024. Unless otherwise indicated below,